IGHE and asthma: Conclusions: Dupilumab significantly reduced severe asthma exacerbations and improved pre-bronchodilator FEV1 across all IgE subgroups in patients with uncontrolled, moderate-to-severe asthma and with baseline blood eosinophils ≥ 150μL.